ABSTRACT
Background Introduced in 2007, the Ozaki procedure has become an attractive option for aortic valve disease. Our objective was to investigate outcomes of the Ozaki procedure in the original Ozaki cohort.
Methods From April 2007 to May 2021, 1,196 consecutive Ozaki procedures were performed at Toho University Ohashi Medical Center. Patient age ranged from 11 to over 90 years, 484 (60%) were male, 50 (4.2%) had previous cardiac surgery, and 155 (13%) were on dialysis. 322 (27%) had bicuspid valves and 28 (2.3%) had infective endocarditis. 651 (54%) had aortic stenosis, 289 (24%) aortic regurgitation, and 87 (7.2%) mixed. 546 (46%) underwent concomitant procedures. Clinical outcomes, echocardiograms, and follow-up data were collected and analyzed for valve performance, and time-to-event analyses were performed for reoperation and mortality. 5023 patient-years of follow-up were available for analysis, with 50% of patients followed >3.2 years and 10% >9 years.
Results Mean cardiopulmonary bypass and aortic clamp times for isolated Ozaki procedures were 151 ± 37 and 105 ± 29 minutes, respectively. Thirty-day mortality was 1.7% (n=20), new stroke 14 (2.6%), new dialysis 41(4.0%), and permanent pacemaker implantation 18 (1.5%). At 6 months, 5 years, and 10 years, peak/mean aortic valve gradients were 14.0/7.4, 15.5/8.0 and 15.5/8.2 mmHg, respectively, and ≥moderate regurgitation was 0.30%/2.9%/6.6%. Left ventricular mass index decreased from 141 ± 52 g/m2 preoperatively to 100 ± 1.1 g/m2 at 6 months and 90 ± 1.8 g/m2 at 10 years. At 10 years, freedom from reoperation was 91.2% and survival 75%.
Conclusion The Ozaki procedure creates good aortic valves with stable low gradients. Regurgitation increased over time, but risk of reoperation was low, supporting continued use.
Competing Interest Statement
Ozaki receives royalties from Tokyo Research Center for Advanced Surgical Technology (TCAST) Co., Ltd. Tokyo, Japan.
Funding Statement
This study was funded in part by the Peter and Elizabeth C. Tower and Family Endowed Chair in Cardiothoracic Research, James and Sharon Kennedy, the Slosburg Family Charitable Trust, and the Stephen and Saundra Spencer Fund for Cardiothoracic Research.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
Cleveland Clinic and Toho university IRB
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Footnotes
Presented at the 103rd Annual Meeting of The American Association for Thoracic Surgery in Los Angeles, May 5-8, 2023
IRB# and date approved: Toho University Ohashi Medical Center #H22067, approved 11/22/2022
Patient consent: Data reported in this study were approved for use in research by the Institutional Review Boards Toho University Ohashi Medical Center and Cleveland Clinic, with an Opt-Out consent process.
Data Availability
The method of the analysis will be made available from the corresponding author on request.
NON-STANDARD ABBREVIATIONS AND ACRONYMS
- AR
- aortic regurgitation
- LV
- left ventricle
- EOA
- effective orifice area
- TAVR
- transcatheter aortic valve replacement